This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Masimo Gets CE Mark for ANI Module, Enhances Root Platform
by Zacks Equity Research
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical Distribution and World Courier and higher revenues might aid AmerisourceBergen (ABC) in Q2 earnings. However, stiff competition might be a dampener.
Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
DENTSPLY SIRONA (XRAY) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher Consumable revenues, product innovation and focus on R&D likely to aid DENTSPLY SIRONA (XRAY) in Q1 earnings. However, contraction is gross margin might be a dampener.
Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.
Here's Why You Should Hold on to STERIS (STE) Stock Now
by Zacks Equity Research
STERIS (STE) has been gaining investors' confidence on consistently positive results.
STERIS (STE) Margin Pressure Hurts, Strategic Growth High
by Zacks Equity Research
Mounting operating expenses are weighing on the bottom line of STERIS (STE).
Why Is Steris (STE) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q3.
Steris (STE) Matches Q3 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 0.00% and 1.21%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in STERIS (STE) Stock Right Now
by Zacks Equity Research
With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.
STERIS Rides on Favorable Industry Trends, Rivalry a Concern
by Zacks Equity Research
STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.
STERIS (STE) Dips on New Restructuring Plan, Layoff Decision
by Zacks Equity Research
STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.
Why Is Steris (STE) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Steris (STE) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Steris (STE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
STERIS (STE) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q2.
Steris (STE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 1.85% and 3.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Steris (STE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) Strategic Growth Strong Amid Several Headwinds
by Zacks Equity Research
STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.
Why Is Steris (STE) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Strategic Growth Strong, Competition a Woe
by Zacks Equity Research
STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.